NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Alphabet-C
GOOG
US Stock MarketDetailed Quotes
AURA Aura Biosciences
- 8.200
- +0.090+1.11%
Close Dec 20 16:00 ET
- 8.200
- 0.0000.00%
Post 16:20 ET
409.60MMarket Cap-4.74P/E (TTM)
8.430High8.010Low612.49KVolume8.030Open8.110Pre Close5.02MTurnover1.78%Turnover RatioLossP/E (Static)49.95MShares12.37852wk High2.34P/B282.44MFloat Cap6.63052wk Low--Dividend TTM34.44MShs Float26.160Historical High--Div YieldTTM5.18%Amplitude5.990Historical Low8.196Avg Price1Lot Size
Trending US Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Aura Biosciences Stock Forum
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-SAR in Patients With Non-Muscle-Invasive Bladder Cancer (Nmibc) in Ongoing Phase 1 Trial! No adverse events
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Aura Biosciences (NASDAQ: AURA) reported positive Phase 2 end of study results for bel-sar (AU-011) in treating early-stage choroidal melanoma (CM). The study showed an 80% tumor control rate and 90% visual acuity preservationamong Phase 3-eligible patients. Bel-sar demonstrated a highly favorable safety profile with no tre...
via @Lnova 📊⚡️📊
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting
In reaction to earnings/guidance:
• $Nutanix (NTNX.US)$ +15.4%, $Pure Storage (PSTG.US)$ +6.8%, $Credo Technology (CRDO.US)$ +5.9%, $Signet Jewelers (SIG.US)$ +3.6%, $SentinelOne (S.US)$ +3.4%, $Five Below (FIVE.US)$ +3.2%, $GMS Inc (GMS.US)$ +1.7%, $The Scotts Miracle (SMG.US)$ +0.9% (also CFO steps down, lowers FY22 FCF guidance, reaffirms all other guidance)
Other news:
• $Turquoise Hill Resources (TRQ.US)$ +12.3% (to be acquired by Rio T...
• $Aura Biosciences (AURA.US)$ +13.9% (reports topline data from study of AU-011)
• $Hyzon Motors (HYZN.US)$ +8.2% (to collaborate with $Schlumberger (SLB.US)$ in decarbonizing oil & gas field operations with high-power fuel cells)
• $Apogee Enterprises (APOG.US)$ +6.3% (In reaction to earnings/guidance)
• $GMS Inc (GMS.US)$ +6% (In reaction to earnings/guidance)
• $Darden Restaurants (DRI.US)$ +4.2% (In reaction to earnings/gui...
No comment yet